Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
₹28 Cr
Revenue (TTM)
₹86 Cr
Net Profit (TTM)
₹-12 Cr
ROE
-17.7 %
ROCE
-4.5 %
P/E Ratio
--
P/B Ratio
0.5
Industry P/E
26.59
EV/EBITDA
-68
Div. Yield
0 %
Debt to Equity
1.3
Book Value
₹41.6
EPS
₹-9
Face value
10
Shares outstanding
13,058,287
CFO
₹49.69 Cr
EBITDA
₹149.67 Cr
Net Profit
₹44.69 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
ANG Lifesciences
| -28.4 | -9.0 | -28.6 | -11.3 | -34.7 | -13.6 | -- |
|
BSE Healthcare
| -4.7 | -5.8 | -5.4 | 1.3 | 23.7 | 14.0 | 10.6 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
ANG Lifesciences
| -35.0 | -34.6 | -42.2 | -74.4 | 1,194.7 | 82.3 | 4.2 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 | 32.1 | -6.8 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
ANG Lifesciences
|
21.2 | 27.6 | 86.2 | -11.8 | -10.0 | -19.1 | -- | 0.5 |
| 2,791.2 | 34,920.1 | 5,201.6 | 1,014.6 | 22.9 | 25 | 34.4 | 7.6 | |
| 7,827.5 | 19,544.3 | 2,177.5 | 200.9 | 11.3 | 26.5 | 97.3 | 23.5 | |
| 1,565.8 | 11,917.5 | 2,089.5 | 622.0 | 31.3 | 20.4 | 19.4 | 3.6 | |
| 1,499.2 | 9,167.3 | 1,196.4 | 149.4 | -- | 27.5 | 61.3 | 13.1 | |
| 1,332.1 | 18,429.0 | 3,078.2 | 469.4 | 26.4 | 14.9 | 42.7 | 5.1 | |
| 1,961.1 | 31,410.1 | 4,193.0 | 753.8 | 22.7 | 20.8 | 41.7 | 7.8 | |
| 4,887.1 | 22,333.8 | 2,482.3 | 853.6 | 33.7 | 18.9 | 26.2 | 5.6 | |
| 4,778.6 | 7,918.9 | 1,348.5 | 293.5 | 28.1 | 50.7 | 27 | 11.4 | |
| 971.2 | 8,938.5 | 4,725.6 | 528.7 | 14.9 | 20.7 | 17.5 | 3.0 |
Sigachi Industries IPO: Information analysis
6 min read•By Arul Selvan and Udhayaprakash
Manufacture of allopathic pharmaceutical preparations
Incorporated
2006
Chairman
--
Managing Director
Rajesh Gupta
Headquarters
Amritsar, Punjab
Website
Looking for more details about ANG Lifesciences India Ltd.’s IPO? Explore our IPO Details page.
Our rating system has guided millions of investors in the past 20 years.
The share price of ANG Lifesciences India Ltd is ₹21.15 (BSE) as of 02-Apr-2026 IST. ANG Lifesciences India Ltd has given a return of -34.73% in the last 3 years.
Since, TTM earnings of ANG Lifesciences India Ltd is negative, P/E ratio is not available.
The P/B ratio of ANG Lifesciences India Ltd is 0.51 times as on 02-Apr-2026, a 89 discount to its peers’ median range of 4.49 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
0.00
|
0.46
|
|
2024
|
0.00
|
0.77
|
|
2023
|
0.00
|
1.15
|
|
2022
|
4.83
|
2.90
|
|
2021
|
2.45
|
1.08
|
The 52-week high and low of ANG Lifesciences India Ltd are Rs 39.70 and Rs 17.63 as of 04-Apr-2026.
ANG Lifesciences India Ltd has a market capitalisation of ₹ 28 Cr as on 02-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in ANG Lifesciences India Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
₹0.89
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.